Hemab Therapeutics Inc. Common Stock

COAG | NASDAQ

$41.38

+$0.96 (+2.38%)

At close: Oct 30, 2026, 3:59 PM ET

$41.66

+$0.28 (+0.68%)

After-hours: Oct 30, 2026, 7:48 PM ET

Fiscal Quarter Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026
Cash & Equivalents	237.37M	49.86M
Short-Term Investments	220.09M	113.67M
Long-Term Investments	n/a	n/a
Other Long-Term Assets	2.29M	4.24M
Receivables	n/a	1.43M
Inventory	n/a	n/a
Other Current Assets	n/a	n/a
Total Current Assets	464M	169.43M
Property-Plant & Equipment	1.5M	1.59M
Goodwill & Intangibles	n/a	n/a
Total Long-Term Assets	3.78M	5.83M
Total Assets	467.78M	175.26M
Account Payables	6.23M	5.68M
Deferred Revenue	n/a	n/a
Short-Term Debt	n/a	n/a
Other Current Liabilities	n/a	1.29M
Total Current Liabilities	12.94M	13.19M
Long-Term Debt	n/a	n/a
Other Long-Term Liabilities	n/a	360.17M
Total Long-Term Liabilities	566K	360.69M
Total Liabilities	13.51M	373.88M
Total Debt	1.03M	1.06M
Book Value	454.27M	-198.62M
Book Value Per Share	15.09	-4.49
Common Stock	454.27M	n/a
Retained Earnings	n/a	-204.55M
Comprehensive Income	n/a	-439K
Shareholders Equity	454.27M	-198.62M
Total Investments	220.09M	113.67M